Published in Medical Letter on the CDC and FDA, September 13th, 2009
That warning has been issued by risk management expert Jeffrey Fetterman, CEO of ParagonRx, a Delaware-based company specializing in optimal medication use, in a blog posted to the company's Website - www.paragonrx.com.
"FDA requires an assessment of REMS performance at intervals no less frequently than 18 months, 3 years and 7 years post...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.